Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971

Journal of Clinical Oncology

Volumn 21, Issue 13, 2003, Pages 2525-2528

  Van Den Bent, M J ^a   Taphoorn, M J B ^b   Brandes, A A ^b   Menten, J ^b   Stupp, R ^b   Frenay, M ^b   Chinot, O ^b   Kros, J M ^b   Van Der Rijt, C C D ^b   Vecht, Ch J ^b   Allgeier, A ^b   Gorlia, T ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE;

ARTICLE; ASTROCYTOMA; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLIOMA; HEMATOLOGIC DISEASE; HUMAN; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIAL TUMOR; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; TREATMENT RESPONSE; ADULT; BRAIN TUMOR; DISEASE COURSE; DRUG ADMINISTRATION; FEMALE; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; PATHOLOGY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OLIGODENDROGLIOMA; TREATMENT OUTCOME;

EID: 0038352148     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.12.015     Document Type: Article

References (15)

1. Cairncross G, Macdonald D, Ludwin S, et al: Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 12:2013-2021, 1994
2. Paleologos N, Macdonald D, Vick NA, et al: Neoadjuvant procarbazine, CCNU and vincristine for anaplastic and aggressive oligodendroglioma. Neurology 53:1141-1143, 1999
3. van den Bent MJ, Kros JM, Heimans JJ, et al: Response rate and prognostic factors of recurrent oligodendroglioma treated with PCV chemotherapy. Neurology 51:1140-1145, 1998
4. Soffietti R, Ruda R, Bradac GB, et al: PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 43:1066-1073, 1998
5. Yung WKA, Prados M, Yaya-Tur R, et al: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 17:2762-2771, 1999
6. Osoba D, Brada M, Yung WKA, et al: Health realted quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. Eur J Cancer 36:1788-1795, 2000
7. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
8. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
9. Macdonald DR, Cascino TL, Schold SC, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990
10. Cairncross JG, Ueki K, Zlatescu MC, et al: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479, 1998
11. van den Bent MJ, Looijenga LHJ, Langenberg K, et al: Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 97:1276-1284, 2003
12. van den Bent MJ, Keime-Guibert F, Brandes AA, et al: Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology 57:340-342, 2001
13. Constanza A, Borgogne M, Nobile M, et al: Temozolomide in recurrent oligodendroglioma: A phase II study. Neuro-Oncology 3:S66, 2001 (abstr, suppl)
14. van den Bent MJ, Chinot O, Boogerd W, et al: EORTC Brain Tumor Group study 26972: Second line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV-chemotherapy-A phase II study. Ann Oncol 14:599-602, 2003
15. Ino Y, Betensky RA, Zlatescu MC, et al: Molecular subtypes of anaplastic oligodendroglioma: Implications for patient management at diagnosis. Clin Cancer Res 7:839-845, 2001